Neglected Tropical Diseases Diagnosis Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others), By Diagnostic Method (Conventional, Molecular/Modern), By Service Type (Centralized Service, POC Service), By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare), By Region & Competition, 2021-2031F
The Global Neglected Tropical Diseases Diagnosis Market is anticipated to grow from USD 6.28 Billion in 2025 to USD 8.01 Billion by 2031, demonstrating a 4.14% CAGR, as it delivers specialized diagnostic technologies like rapid diagnostic tests, molecular assays, and microscopy solutions for identifying parasitic, viral, and bacterial pathogens in low-resource settings. This expansion is primarily driven by the World Health Organization’s 2030 Roadmap for disease elimination and strengthened public-private partnerships improving healthcare infrastructure, along with the integration of routine screening into national universal health coverage. Significant international funding and philanthropic support are also crucial, providing capital for affordable, high-performance diagnostic tool development and manufacturing scale-up, while robust government initiatives and disease elimination programs necessitate widespread surveillance and confirmation testing to validate disease clearance. These efforts are vital given that approximately 1.495 billion people globally required interventions against neglected tropical diseases in 2023, highlighting the critical need for diagnostic capabilities to manage this substantial disease burden affecting populations, including half a billion children. A critical challenge impeding market expansion, however, is the financial sustainability of diagnostic programs in endemic regions. The sector's substantial reliance on external donor funding, rather than consistent commercial revenue, leads to irregular and unpredictable procurement cycles. This volatility prevents manufacturers from scaling production and discourages long-term investment in distribution networks, as demand is often dictated by available international aid rather than actual clinical necessity. Such economic dependence is particularly concerning given the recent 41% decrease in official development assistance for neglected tropical diseases between 2018 and 2023, leaving domestic health budgets in affected nations struggling to bridge the capital gap and thereby stalling the broader deployment of essential diagnostic tools. Nevertheless, the market is experiencing transformative trends such as the integration of Artificial Intelligence in microscopy automation, which addresses the shortage of skilled diagnosticians by automating parasitic pathogen detection, significantly reducing manual error and increasing diagnostic throughput. Simultaneously, the widespread adoption of multiplex lateral flow assays facilitates the concurrent detection of multiple neglected tropical diseases at the point of care, providing vital decentralized screening capabilities that enable immediate treatment decisions without relying on distant laboratory infrastructure, a shift highlighted by the procurement of over 1 million such diagnostic tests for five specific NTDs in 2024.
Market Driver
Growing international funding and philanthropic support are pivotal in accelerating the Global Neglected Tropical Diseases Diagnosis Market by bridging financial gaps for research and development. This influx of capital facilitates the creation of affordable, high-performance diagnostic tools tailored for low-resource settings and supports the expansion of manufacturing capabilities. For instance, the GHIT Fund awarded approximately USD 11.6 million in October 2025 to strengthen product development pipelines for tuberculosis and neglected tropical diseases, de-risking novel diagnostic development and ensuring testing solutions reach remote communities where market forces alone may not incentivize innovation. Furthermore, robust government initiatives and disease elimination programs significantly propel market expansion as nations align with the World Health Organization’s 2030 Roadmap. These state-led efforts demand widespread surveillance and confirmation testing to validate disease clearance, directly driving the procurement of rapid diagnostic tests and molecular assays. As of January 2025, 54 countries have successfully eliminated at least one neglected tropical disease, underscoring the effectiveness of these rigorous testing-and-treat strategies. However, sustained diagnostic vigilance remains crucial, especially since June 2025 data indicates that half a billion children globally are impacted by neglected tropical diseases, creating persistent demand for pediatric-adapted diagnostic solutions to maintain elimination gains.
Market Challenge
The financial sustainability of diagnostic programs in endemic regions represents a critical barrier impeding the growth of the Global Neglected Tropical Diseases Diagnosis Market. The sector's heavy reliance on external donor funding, rather than consistent commercial revenue, often leads to irregular and unpredictable procurement cycles. This volatility hinders manufacturers' ability to scale production and discourages long-term investment in distribution networks, as demand is frequently dictated by the availability of international aid rather than actual clinical necessity. When donor priorities shift or global budgets contract, testing initiatives in low-resource settings face immediate shortages, disrupting the continuity of disease monitoring. This economic dependence is particularly damaging given recent contractions in global health financing; official development assistance specifically for neglected tropical diseases decreased by 41% between 2018 and 2023. This substantial reduction in external support exposes the market's fragility, as limited domestic health budgets in affected nations are often unable to bridge the capital gap. Consequently, the inability to secure consistent funding models stalls the broader deployment of essential diagnostic tools, directly restricting the market's potential for expansion.
Market Trends
The integration of Artificial Intelligence (AI) in microscopy automation is emerging as a transformative trend, directly addressing the critical shortage of skilled diagnosticians in endemic regions by automating the detection of parasitic pathogens. This technology employs advanced algorithms to analyze digital sample images, significantly reducing manual error and increasing diagnostic throughput for diseases such as schistosomiasis and soil-transmitted helminthiasis. A notable collaborative effort, the MultiplexAI Project, launched by a consortium of nine African and European institutions in September 2025, aims to develop and validate these mobile-connected AI tools for primary care settings. Simultaneously, the widespread adoption of multiplex lateral flow assays is enabling the concurrent detection of multiple neglected tropical diseases at the point of care. These sophisticated rapid tests are vital for decentralized screening models, empowering healthcare workers to make immediate treatment decisions without relying on distant laboratory infrastructure. The scale of this operational shift is substantial, as highlighted by the World Health Organization, which facilitated the procurement of over 1 million diagnostic tests for five specific NTDs in 2024, reflecting the growing reliance on versatile rapid diagnostics to support transmission interruption in remote communities.
Key Market Players
In this report, the Global Neglected Tropical Diseases Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Diseases Diagnosis Market.
Available Customizations:
Global Neglected Tropical Diseases Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Market Driver
Growing international funding and philanthropic support are pivotal in accelerating the Global Neglected Tropical Diseases Diagnosis Market by bridging financial gaps for research and development. This influx of capital facilitates the creation of affordable, high-performance diagnostic tools tailored for low-resource settings and supports the expansion of manufacturing capabilities. For instance, the GHIT Fund awarded approximately USD 11.6 million in October 2025 to strengthen product development pipelines for tuberculosis and neglected tropical diseases, de-risking novel diagnostic development and ensuring testing solutions reach remote communities where market forces alone may not incentivize innovation. Furthermore, robust government initiatives and disease elimination programs significantly propel market expansion as nations align with the World Health Organization’s 2030 Roadmap. These state-led efforts demand widespread surveillance and confirmation testing to validate disease clearance, directly driving the procurement of rapid diagnostic tests and molecular assays. As of January 2025, 54 countries have successfully eliminated at least one neglected tropical disease, underscoring the effectiveness of these rigorous testing-and-treat strategies. However, sustained diagnostic vigilance remains crucial, especially since June 2025 data indicates that half a billion children globally are impacted by neglected tropical diseases, creating persistent demand for pediatric-adapted diagnostic solutions to maintain elimination gains.
Market Challenge
The financial sustainability of diagnostic programs in endemic regions represents a critical barrier impeding the growth of the Global Neglected Tropical Diseases Diagnosis Market. The sector's heavy reliance on external donor funding, rather than consistent commercial revenue, often leads to irregular and unpredictable procurement cycles. This volatility hinders manufacturers' ability to scale production and discourages long-term investment in distribution networks, as demand is frequently dictated by the availability of international aid rather than actual clinical necessity. When donor priorities shift or global budgets contract, testing initiatives in low-resource settings face immediate shortages, disrupting the continuity of disease monitoring. This economic dependence is particularly damaging given recent contractions in global health financing; official development assistance specifically for neglected tropical diseases decreased by 41% between 2018 and 2023. This substantial reduction in external support exposes the market's fragility, as limited domestic health budgets in affected nations are often unable to bridge the capital gap. Consequently, the inability to secure consistent funding models stalls the broader deployment of essential diagnostic tools, directly restricting the market's potential for expansion.
Market Trends
The integration of Artificial Intelligence (AI) in microscopy automation is emerging as a transformative trend, directly addressing the critical shortage of skilled diagnosticians in endemic regions by automating the detection of parasitic pathogens. This technology employs advanced algorithms to analyze digital sample images, significantly reducing manual error and increasing diagnostic throughput for diseases such as schistosomiasis and soil-transmitted helminthiasis. A notable collaborative effort, the MultiplexAI Project, launched by a consortium of nine African and European institutions in September 2025, aims to develop and validate these mobile-connected AI tools for primary care settings. Simultaneously, the widespread adoption of multiplex lateral flow assays is enabling the concurrent detection of multiple neglected tropical diseases at the point of care. These sophisticated rapid tests are vital for decentralized screening models, empowering healthcare workers to make immediate treatment decisions without relying on distant laboratory infrastructure. The scale of this operational shift is substantial, as highlighted by the World Health Organization, which facilitated the procurement of over 1 million diagnostic tests for five specific NTDs in 2024, reflecting the growing reliance on versatile rapid diagnostics to support transmission interruption in remote communities.
Key Market Players
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories Ltd.
- Thermo Fisher Scientific Inc.
- ZeptoMetrix LLC
- InBios International, Inc.
- DiaSys Diagnostics Systems GmbH
- Genome Diagnostics Pvt. Ltd.
- Omega Diagnostics Group Plc
- Oscar Medicare Pvt Ltd.
- Coris BioConcept
In this report, the Global Neglected Tropical Diseases Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Neglected Tropical Diseases Diagnosis Market, By Disease
- Dengue
- Chikungunya
- Rabies
- Buruli Ulcer
- Yaws
- Lymphatic Filariasis
- Taeniasis/Cysticercosis
- Dracunculiasis
- others
- Neglected Tropical Diseases Diagnosis Market, By Diagnostic Method
- Conventional
- Molecular/Modern
- Neglected Tropical Diseases Diagnosis Market, By Service Type
- Centralized Service
- POC Service
- Neglected Tropical Diseases Diagnosis Market, By End Use
- Clinical Labs
- Hospital/Clinics
- Home Healthcare
- Neglected Tropical Diseases Diagnosis Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Diseases Diagnosis Market.
Available Customizations:
Global Neglected Tropical Diseases Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others)
5.2.2. By Diagnostic Method (Conventional, Molecular/Modern)
5.2.3. By Service Type (Centralized Service, POC Service)
5.2.4. By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease
6.2.2. By Diagnostic Method
6.2.3. By Service Type
6.2.4. By End Use
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Neglected Tropical Diseases Diagnosis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease
6.3.1.2.2. By Diagnostic Method
6.3.1.2.3. By Service Type
6.3.1.2.4. By End Use
6.3.2. Canada Neglected Tropical Diseases Diagnosis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease
6.3.2.2.2. By Diagnostic Method
6.3.2.2.3. By Service Type
6.3.2.2.4. By End Use
6.3.3. Mexico Neglected Tropical Diseases Diagnosis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease
6.3.3.2.2. By Diagnostic Method
6.3.3.2.3. By Service Type
6.3.3.2.4. By End Use
7. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease
7.2.2. By Diagnostic Method
7.2.3. By Service Type
7.2.4. By End Use
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Neglected Tropical Diseases Diagnosis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease
7.3.1.2.2. By Diagnostic Method
7.3.1.2.3. By Service Type
7.3.1.2.4. By End Use
7.3.2. France Neglected Tropical Diseases Diagnosis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease
7.3.2.2.2. By Diagnostic Method
7.3.2.2.3. By Service Type
7.3.2.2.4. By End Use
7.3.3. United Kingdom Neglected Tropical Diseases Diagnosis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease
7.3.3.2.2. By Diagnostic Method
7.3.3.2.3. By Service Type
7.3.3.2.4. By End Use
7.3.4. Italy Neglected Tropical Diseases Diagnosis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease
7.3.4.2.2. By Diagnostic Method
7.3.4.2.3. By Service Type
7.3.4.2.4. By End Use
7.3.5. Spain Neglected Tropical Diseases Diagnosis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease
7.3.5.2.2. By Diagnostic Method
7.3.5.2.3. By Service Type
7.3.5.2.4. By End Use
8. ASIA PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease
8.2.2. By Diagnostic Method
8.2.3. By Service Type
8.2.4. By End Use
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Neglected Tropical Diseases Diagnosis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease
8.3.1.2.2. By Diagnostic Method
8.3.1.2.3. By Service Type
8.3.1.2.4. By End Use
8.3.2. India Neglected Tropical Diseases Diagnosis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease
8.3.2.2.2. By Diagnostic Method
8.3.2.2.3. By Service Type
8.3.2.2.4. By End Use
8.3.3. Japan Neglected Tropical Diseases Diagnosis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease
8.3.3.2.2. By Diagnostic Method
8.3.3.2.3. By Service Type
8.3.3.2.4. By End Use
8.3.4. South Korea Neglected Tropical Diseases Diagnosis Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease
8.3.4.2.2. By Diagnostic Method
8.3.4.2.3. By Service Type
8.3.4.2.4. By End Use
8.3.5. Australia Neglected Tropical Diseases Diagnosis Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease
8.3.5.2.2. By Diagnostic Method
8.3.5.2.3. By Service Type
8.3.5.2.4. By End Use
9. MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease
9.2.2. By Diagnostic Method
9.2.3. By Service Type
9.2.4. By End Use
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Neglected Tropical Diseases Diagnosis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease
9.3.1.2.2. By Diagnostic Method
9.3.1.2.3. By Service Type
9.3.1.2.4. By End Use
9.3.2. UAE Neglected Tropical Diseases Diagnosis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease
9.3.2.2.2. By Diagnostic Method
9.3.2.2.3. By Service Type
9.3.2.2.4. By End Use
9.3.3. South Africa Neglected Tropical Diseases Diagnosis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease
9.3.3.2.2. By Diagnostic Method
9.3.3.2.3. By Service Type
9.3.3.2.4. By End Use
10. SOUTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease
10.2.2. By Diagnostic Method
10.2.3. By Service Type
10.2.4. By End Use
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Neglected Tropical Diseases Diagnosis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease
10.3.1.2.2. By Diagnostic Method
10.3.1.2.3. By Service Type
10.3.1.2.4. By End Use
10.3.2. Colombia Neglected Tropical Diseases Diagnosis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease
10.3.2.2.2. By Diagnostic Method
10.3.2.2.3. By Service Type
10.3.2.2.4. By End Use
10.3.3. Argentina Neglected Tropical Diseases Diagnosis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease
10.3.3.2.2. By Diagnostic Method
10.3.3.2.3. By Service Type
10.3.3.2.4. By End Use
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. F. Hoffmann-La Roche Ltd
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Abbott Laboratories Ltd.
15.3. Thermo Fisher Scientific Inc.
15.4. ZeptoMetrix LLC
15.5. InBios International, Inc.
15.6. DiaSys Diagnostics Systems GmbH
15.7. Genome Diagnostics Pvt. Ltd.
15.8. Omega Diagnostics Group Plc
15.9. Oscar Medicare Pvt Ltd.
15.10. Coris BioConcept
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others)
5.2.2. By Diagnostic Method (Conventional, Molecular/Modern)
5.2.3. By Service Type (Centralized Service, POC Service)
5.2.4. By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease
6.2.2. By Diagnostic Method
6.2.3. By Service Type
6.2.4. By End Use
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Neglected Tropical Diseases Diagnosis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease
6.3.1.2.2. By Diagnostic Method
6.3.1.2.3. By Service Type
6.3.1.2.4. By End Use
6.3.2. Canada Neglected Tropical Diseases Diagnosis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease
6.3.2.2.2. By Diagnostic Method
6.3.2.2.3. By Service Type
6.3.2.2.4. By End Use
6.3.3. Mexico Neglected Tropical Diseases Diagnosis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease
6.3.3.2.2. By Diagnostic Method
6.3.3.2.3. By Service Type
6.3.3.2.4. By End Use
7. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease
7.2.2. By Diagnostic Method
7.2.3. By Service Type
7.2.4. By End Use
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Neglected Tropical Diseases Diagnosis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease
7.3.1.2.2. By Diagnostic Method
7.3.1.2.3. By Service Type
7.3.1.2.4. By End Use
7.3.2. France Neglected Tropical Diseases Diagnosis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease
7.3.2.2.2. By Diagnostic Method
7.3.2.2.3. By Service Type
7.3.2.2.4. By End Use
7.3.3. United Kingdom Neglected Tropical Diseases Diagnosis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease
7.3.3.2.2. By Diagnostic Method
7.3.3.2.3. By Service Type
7.3.3.2.4. By End Use
7.3.4. Italy Neglected Tropical Diseases Diagnosis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease
7.3.4.2.2. By Diagnostic Method
7.3.4.2.3. By Service Type
7.3.4.2.4. By End Use
7.3.5. Spain Neglected Tropical Diseases Diagnosis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease
7.3.5.2.2. By Diagnostic Method
7.3.5.2.3. By Service Type
7.3.5.2.4. By End Use
8. ASIA PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease
8.2.2. By Diagnostic Method
8.2.3. By Service Type
8.2.4. By End Use
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Neglected Tropical Diseases Diagnosis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease
8.3.1.2.2. By Diagnostic Method
8.3.1.2.3. By Service Type
8.3.1.2.4. By End Use
8.3.2. India Neglected Tropical Diseases Diagnosis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease
8.3.2.2.2. By Diagnostic Method
8.3.2.2.3. By Service Type
8.3.2.2.4. By End Use
8.3.3. Japan Neglected Tropical Diseases Diagnosis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease
8.3.3.2.2. By Diagnostic Method
8.3.3.2.3. By Service Type
8.3.3.2.4. By End Use
8.3.4. South Korea Neglected Tropical Diseases Diagnosis Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease
8.3.4.2.2. By Diagnostic Method
8.3.4.2.3. By Service Type
8.3.4.2.4. By End Use
8.3.5. Australia Neglected Tropical Diseases Diagnosis Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease
8.3.5.2.2. By Diagnostic Method
8.3.5.2.3. By Service Type
8.3.5.2.4. By End Use
9. MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease
9.2.2. By Diagnostic Method
9.2.3. By Service Type
9.2.4. By End Use
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Neglected Tropical Diseases Diagnosis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease
9.3.1.2.2. By Diagnostic Method
9.3.1.2.3. By Service Type
9.3.1.2.4. By End Use
9.3.2. UAE Neglected Tropical Diseases Diagnosis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease
9.3.2.2.2. By Diagnostic Method
9.3.2.2.3. By Service Type
9.3.2.2.4. By End Use
9.3.3. South Africa Neglected Tropical Diseases Diagnosis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease
9.3.3.2.2. By Diagnostic Method
9.3.3.2.3. By Service Type
9.3.3.2.4. By End Use
10. SOUTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease
10.2.2. By Diagnostic Method
10.2.3. By Service Type
10.2.4. By End Use
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Neglected Tropical Diseases Diagnosis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease
10.3.1.2.2. By Diagnostic Method
10.3.1.2.3. By Service Type
10.3.1.2.4. By End Use
10.3.2. Colombia Neglected Tropical Diseases Diagnosis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease
10.3.2.2.2. By Diagnostic Method
10.3.2.2.3. By Service Type
10.3.2.2.4. By End Use
10.3.3. Argentina Neglected Tropical Diseases Diagnosis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease
10.3.3.2.2. By Diagnostic Method
10.3.3.2.3. By Service Type
10.3.3.2.4. By End Use
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. F. Hoffmann-La Roche Ltd
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Abbott Laboratories Ltd.
15.3. Thermo Fisher Scientific Inc.
15.4. ZeptoMetrix LLC
15.5. InBios International, Inc.
15.6. DiaSys Diagnostics Systems GmbH
15.7. Genome Diagnostics Pvt. Ltd.
15.8. Omega Diagnostics Group Plc
15.9. Oscar Medicare Pvt Ltd.
15.10. Coris BioConcept
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
